Expert Interview
Discussing investigational therapies in CRC, including DKN-01+bevacizumab+chemo (triple combo) in 2nd line from Leap Therapeutics and onvansertib, a PLK1 inhibitor in 1st and 2nd line from Cardiff Oncology.
Ticker(s): CRDF, LPTXInstitution: Mayo Clinic
- Medical oncologist and Professor in the Division of Hematology/Medical Oncology at Mayo Clinic.
- Conducts clinical and translational research focused on developing anti-cancer agents for patients with GI Cancers.
- Research focused on agents that target the multiple facets of cancer, including genetic and epigenetic drivers, as well as feeding microenvironment and immune milieu.
Roughly how many patients with colorectal cancer do you manage?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for DKN-01+bevacizumab+chemo (triple combo)? For onvansertib?
Added By: c_adminAny red flags in Onvansertib Ph1/2 mCRC data thus far?
Added By: user2b8bb296Onvansertib. 2L Ph1/2 ORR across two trials is 13/19 = 68% in bev naive. How likely is it that bev is driving this vs bev + onvansertib? Does the theorized synergy MOA for bev + onv make sense? It's supposedly related to HIF.
Added By: user2b8bb296Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
